The Brigham and Dana-Farber Board Review in Hematology and Oncology 2020

The Brigham and Dana-Farber Board Review in Hematology and Oncology 2020

Regular price
$110.00
Sale price
$110.00

    The Brigham and Dana-Farber Board Review in Hematology and Oncology

    Brigham and Women’s Hospital Board Review

    This comprehensive CME program offers an in-depth, case-base review of the clinical essentials in hematology and oncology. Ideal for MOC.

    Overview


    Improve Patient Care in Hematology and Oncology

    The Brigham and Dana-Farber Board Review in Hematology and Oncology will help improve clinical practice gaps in hematology and oncology derived from the American Board of Internal Medicine (ABIM) certification/recertification requirements. In this CME program, expert speakers address relevant topics in case-based board review presentations. Improve patient care by learning to:

    • Perform differential diagnosis of complex hematologic and oncologic disorders
    • Identify and apply current therapeutic options for hematologic and oncologic disorders
    • Evaluate and interpret up-to-date literature relevant to hematology and oncology
    • Illustrate knowledge of pathophysiology of hematologic and oncologic disorders
    • Apply new knowledge to the ABIM certification/recertification hematology and oncology examinations

    Topics/Speakers

    • Molecular Genetics of Cancer - Nikhil Wagle, MD
    • Advances in Cancer Drug Development - Geoffrey I. Shapiro, MD, PhD
    • Infections in Cancer Patients - Lindsey Baden, MD
    • Symptom Management in Patients with Cancer - Andrew J. Lawton, MD
    • Communication: The Key to Excellence in End-of-Life Care - Rachelle E. Bernacki, MD
    • Biology of Hematopoietic Stem Cell Transplantation - Robert J. Soiffer, MD
    • Biology of Acute Leukemia and Myelodysplastic Syndromes - Benjamin L. Ebert, MD, PhD
    • Acute Leukemias - Daniel J. DeAngelo, MD, PhD
    • Myelodysplastic Syndrome - David P. Steensma, MD
    • Chronic Myelogenous Leukemia - Marlise R. Luskin, MD
    • Myeloproliferative Syndromes - Ann M. Mullally, MD
    • Multiple Myeloma - Kenneth C. Anderson, MD
    • Waldenstrom Macroglobulemia and Amyloidosis - Jorge J. Castillo, MD
    • Low Grade Lymphomas - Caron A. Jacobson, MD
    • High Grade Lymphomas - Eric D. Jacobsen, MD
    • Hodgkin's Lymphoma - Jennifer L. Crombie, MD
    • Diagnosis and Treatment of CLL and Related B Cell Malignancies - Matthew S. Davids, MD
    • Head and Neck Cancer - Robert I. Haddad, MD
    • Natural History, Screening, Surgery and Small Cell Lung Cancer - Bruce E. Johnson, MD
    • Non Small Cell Lung Cancer - Mark Awad, MD, PhD
    • Mesothelioma and Thymoma - David M. Jackman, MD
    • Thyroid Cancer - Jochen Lorch, MD
    • Carcinoid and Pancreatic Neuroendocrine Tumors - Jennifer Ang Chan, MD
    • Esophageal and Gastric Cancer - Peter C. Enzinger, MD
    • Pancreatic and Hepatobiliary Cancer - Brian M. Wolpin, MD
    • Anal Cancers - Robert J. Mayer, MD
    • Colorectal Cancers - Robert J. Mayer, MD
    • Gastrointestinal Cancer: Genetic Syndromes - Matthew Yurgelun, MD
    • Germ Cell Tumor: Maximizing Cure While Minimizing the Burden of Therapy - Mark M. Pomerantz, MD
    • Renal and Bladder Cancer - Guru P. Sonpavde, MBBS
    • Prostate Cancer Part I: Overview and Management of Localized Disease - Atish D. Choudhury, MD, PhD
    • Prostate Cancer Part II: Management of Disseminated Prostate Cancer - Atish D. Choudhury, MD, PhD
    • Melanoma - F. Stephen Hodi, MD
    • Sarcomas and Gastrointestinal Stromal Tumors (GIST) - George D. Demetri, MD
    • Ovarian Cancer - Ursula A. Matulonis, MD
    • Cervical and Endometrial Cancer - Panagiotis A. Konstantinopoulos, MD, PhD
    • Neuro-oncology - David A. Reardon, MD
    • Breast Cancer: Risk Factors, Genetics, Screening, and Prevention - Judy E. Garber, MD, MPH
    • Multimodality Therapy for Early Stage Breast Cancer: Part 1 - Surgery and Radiation - Harold J. Burstein, MD, PhD
    • Multimodality Therapy for Early Stage Breast Cancer: Part 2 - Systemic Therapy - Harold J. Burstein, MD, PhD
    • Management of Metastatic Breast Cancer - Erica Mayer, MD, MPH
    • Breast Cancer Survivorship - Ann H. Partridge, MD, MPH
    • Hematopoiesis and Cytokines - David T. Scadden, MD
    • Acquired Bone Marrow Failure - Julie-Aurore Losman, MD, PhD
    • Congenital Bone Marrow Failure - Akiko Shimamura, MD, PhD
    • Hemophagocytic Syndromes and Related Immunodeficiencies - Barbara A. Degar, MD
    • Anemia: An Overview - Ronald P. McCaffrey, MD
    • Iron Deficiency and Iron Overload - Mark D. Fleming, MD, PhD
    • Immune Hemolytic Anemia - Richard M. Kaufman, MD
    • Non-immune Hemolytic Anemia - David E. Golan, PhD, MD
    • Sickle Cell Disease - Maureen M. Achebe, MD, MPH
    • Thalassemia and Other Hemoglobinopathies - Matthew M. Heeney, MD
    • Disorders of Neutrophils - Nancy Berliner, MD
    • Acquired Thrombocytopenias - Elisabeth M. Battinelli, MD, PhD
    • Hemophilia - Aric D. Parnes, MD
    • Von Willebrand Disease and Congenital Platelet Disorders - Nathan T. Connell, MD, MPH
    • Congenital and Acquired Thrombophilia - Kenneth A. Bauer, MD
    • Use of Direct Oral Anticoagulants in Clinical Practice - Jean M. Connors, MD
    • Transfusion Medicine for the Clinician - Walter H. Dzik, MD

     

    Accreditation

    Oakstone Publishing is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Designation

    Oakstone Publishing designates this enduring material for a maximum of 44 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 44 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion informaion to ACCME for the purpose of granting ABIM MOC credit.

    Date of Original Release: April 15, 2020
    Termination Date: April 15, 2023

    CME credit is awarded upon successful completion of a course evaluation and post-test.

    Learning Objectives

    Upon completion of this activity, the participant will be able to:

    • Apply current/recommended Hematology and Oncology guidelines in clinical practice
    • Perform differential diagnosis of complex clinical presentations related to Hematologic and Oncologic disorders
    • Identify/apply current therapeutic options for specific Hematologic and Oncologic disorders
    • Review and interpret up-to-date literature relevant to clinical practice in Hematology and Oncology
    • Demonstrate knowledge of pathophysiology as it applies to management of Hematology and Oncology disorders
    • Apply knowledge gained to the ABIM Certification/Recertification Hematology and Oncology examinations

    Intended Audience

    The activity was planned for fellows/trainees, practicing Hematology and Oncology specialists (MDs), and other professional affiliates (internists with an interest in Hematology and Oncology) who are preparing to take ABIM Board Review or Recertification Examinations, or who seek CME activities to improve patient care in the areas of Hematology and Oncology Medicine.